TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02938312

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Only
Description: Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Plus
Description: Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
Study: NCT02398396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics
Description: 4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
Study: NCT04286399

Intervention type: DRUG
Group type: OTHER
Intervention: Renin-angiotensin-aldosterone system inhibitors
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.

Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.

Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study: NCT01146834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib (Velcade)
Description: 1.3 mg/m2 IVP on days 1, 4, 8 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib (Velcade)
Description: 1.3 mg/m2 IVP on days 1, 4, 8 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib (Velcade)
Description: 1.3 mg/m2 IVP on days 1, 4, 8 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
Study: NCT02276157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct peroral cholangioscopy
Description: The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct peroral cholangioscopy
Description: The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary.
Study: NCT01883323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: i.v., 60mg/kg per day for 2 days
Study: NCT04452591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cretostimogene Grenadenorepvec
Description: Engineered Oncolytic Adenovirus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent.
Study: NCT01146834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
Study: NCT04452591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n-dodecyl-B-D-maltoside
Description: Transduction-enhancing agent.
Study: NCT04322357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
Study: NCT01146834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
Study: NCT03353246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfraScanner 2000™
Description: The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
Study: NCT04322357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home Exercise Training
Description: For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone plus exercise
Description: Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
Study: NCT04188028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 5 MG
Description: dextromethorphan 5 mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 5 MG
Description: dextromethorphan 5 mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 10Mg Tablet
Description: Paroxetine 10 mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20Mg Tablet
Description: Paroxetine 20 mg po
Study: NCT06263686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurised yoghurt
Description: Pasteurised (heat treated) natural yoghurt containing \<15 CFU/g of Lactobacillus delbrueckii bulgacirus and \<15 CFU/g of Streptococcus thermophilus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh yoghurt
Description: containing ≥ 108 CFU/g of Lactobacillus delbrueckii bulgacirus and ≥ 108 CFU/g of Streptococcus thermophilus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterilised yoghurt
Description: Not containing viable bacteria
Study: NCT03838978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso Knee System (Implantable Shock Absorber)
Description: The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
Study: NCT03480672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Description: intravenous application, 12 months, in 3-week cycle (q3w) 200 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adjuvant radiochemotherapy
Description: adjuvant radiochemotherapy with cisplatin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant radiochemotherapy
Description: adjuvant radiochemotherapy with cisplatin
Study: NCT04225871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Daily subcutaneous (SC) injection
Study: NCT03523091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100Unit Injection
Description: Initial treatment with the option of repeat injections every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100Unit Injection
Description: Initial treatment with the option of repeat injections every 3 months
Study: NCT02490982

Intervention type: DRUG
Intervention: Teriflunomide
Description: The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
Study: NCT01105572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intel Health Guide
Description: An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Case Management
Description: Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
Study: NCT04472806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy in combination with Endostar
Description: chemotherapy+ Endostar
Study: NCT05255718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia juice
Description: Once daily dose of 100 mL of aronia juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
Study: NCT04658615

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-surgical periodontal therapy
Description: A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-surgical periodontal therapy
Description: A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
Study: NCT02989662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Participants receive 6 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Participants receive 6 doses
Study: NCT02233868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: connectivity
Description: Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: connectivity
Description: Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neuroinflammation
Description: The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neuroinflammation
Description: The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofunction
Description: To assess regional brain glucose metabolism.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofunction
Description: To assess regional brain glucose metabolism.
Study: NCT01875601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-15 (rhIL-15)
Description: Continuous infusion rhIL15 IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell Infusion
Description: Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell Infusion
Description: Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
Study: NCT02699307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: OT led counseling
Study: NCT03477812

Intervention type: DEVICE
Intervention: Polysomnography (Full sleep registration)
Description: For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.

Intervention type: DEVICE
Intervention: Polysomnography (Full sleep registration)
Description: For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.

Intervention type: DEVICE
Intervention: Polysomnography (Full sleep registration)
Description: For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
Study: NCT03104543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 30 minute education session; 15 minute booster session at 4 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Test results only
Description: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Study: NCT01836354

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DESERVE education
Description: Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
Study: NCT02740556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HepCure ToolKit
Description: HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HepCure ToolKit
Description: HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdhereTech Active Features
Description: AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AdhereTech Passive Monitoring
Description: AdhereTech passively monitors adherence (no chimes or reminders)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AdhereTech Passive Monitoring
Description: AdhereTech passively monitors adherence (no chimes or reminders)
Study: NCT04573985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious game Eurekoi intervention
Description: 1 session in group using the serious game eurekoi
Study: NCT03894800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (C)
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study: NCT03396159

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mini fluid challenge
Description: mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
Study: NCT04743648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Innovative Thinking Development Program (ITDP)
Description: With the implementation of the program, nursing students are expected to develop innovative thinking skills.